Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of NKTR-118 (naloxegol) in opioid-induced constipation
NCT01336205Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2011
- Primary completion
- Dec 2012
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of naloxegol in opioid-induced constipation (OIC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of Patients Experiencing at Least One Adverse Event at 52 weeks, Incidence of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product at 52 weeks and 1 more. Started Apr 2011; status: completed.
02
Drugs
naloxegol
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT01336205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01336205.